BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 29448300)

  • 1. Identification of preoperative factors associated with outcomes following surgical management of intra-abdominal recurrent or metastatic GIST following neoadjuvant tyrosine kinase inhibitor therapy.
    Roland CL; Bednarski BK; Watson K; Torres KE; Cormier JN; Wang WL; Lazar AJ; Somaiah N; Hunt KK; Feig BW
    J Surg Oncol; 2018 Apr; 117(5):879-885. PubMed ID: 29448300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of prognostic factors impacting oncologic outcomes after neoadjuvant tyrosine kinase inhibitor therapy for gastrointestinal stromal tumors.
    Bednarski BK; Araujo DM; Yi M; Torres KE; Lazar A; Trent JC; Cormier JN; Pisters PW; Lev DC; Pollock RE; Feig BW; Hunt KK
    Ann Surg Oncol; 2014 Aug; 21(8):2499-505. PubMed ID: 24639192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term survival outcome with tyrosine kinase inhibitors and surgical intervention in patients with metastatic or recurrent gastrointestinal stromal tumors: A 14-year, single-center experience.
    Kim JH; Ryu MH; Yoo C; Chae H; Na H; Beck M; Kim BS; Yoo MW; Yook JH; Kim BS; Kim KH; Kim CW; Kang YK
    Cancer Med; 2019 Mar; 8(3):1034-1043. PubMed ID: 30693663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative imatinib for patients with primary unresectable or metastatic/recurrent gastrointestinal stromal tumor.
    Shen C; Chen H; Yin Y; Chen J; Zhang B; Chen Z; Chen J
    Clinics (Sao Paulo); 2014 Nov; 69(11):758-62. PubMed ID: 25518034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib.
    Andtbacka RH; Ng CS; Scaife CL; Cormier JN; Hunt KK; Pisters PW; Pollock RE; Benjamin RS; Burgess MA; Chen LL; Trent J; Patel SR; Raymond K; Feig BW
    Ann Surg Oncol; 2007 Jan; 14(1):14-24. PubMed ID: 17072676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of metastasectomy for recurrent/metastatic gastrointestinal stromal tumors based on an analysis of the Kinki GIST registry.
    Sato S; Tsujinaka T; Masuzawa T; Yamamoto K; Takahashi T; Yamashita Y; Fujita J; Takagi M; Hirota S; Nishida T
    Surg Today; 2017 Jan; 47(1):58-64. PubMed ID: 27194124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surgical Management of Metastatic Gastrointestinal Stromal Tumors.
    Yonkus JA; Alva-Ruiz R; Grotz TE
    Curr Treat Options Oncol; 2021 Mar; 22(5):37. PubMed ID: 33743084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132.
    Wang D; Zhang Q; Blanke CD; Demetri GD; Heinrich MC; Watson JC; Hoffman JP; Okuno S; Kane JM; von Mehren M; Eisenberg BL
    Ann Surg Oncol; 2012 Apr; 19(4):1074-80. PubMed ID: 22203182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of operative therapy in treatment of metastatic gastrointestinal stromal tumors.
    Zaydfudim V; Okuno SH; Que FG; Nagorney DM; Donohue JH
    J Surg Res; 2012 Oct; 177(2):248-54. PubMed ID: 22831567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 'CaboGIST'.
    Schöffski P; Mir O; Kasper B; Papai Z; Blay JY; Italiano A; Benson C; Kopeckova K; Ali N; Dileo P; LeCesne A; Menge F; Cousin S; Wardelmann E; Wozniak A; Marreaud S; Litiere S; Zaffaroni F; Nzokirantevye A; Vanden Bempt I; Gelderblom H
    Eur J Cancer; 2020 Jul; 134():62-74. PubMed ID: 32470848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytoreductive Surgery for Metastatic Gastrointestinal Stromal Tumors Treated With Tyrosine Kinase Inhibitors: A 2-institutional Analysis.
    Fairweather M; Balachandran VP; Li GZ; Bertagnolli MM; Antonescu C; Tap W; Singer S; DeMatteo RP; Raut CP
    Ann Surg; 2018 Aug; 268(2):296-302. PubMed ID: 28448384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience.
    Rutkowski P; Gronchi A; Hohenberger P; Bonvalot S; Schöffski P; Bauer S; Fumagalli E; Nyckowski P; Nguyen BP; Kerst JM; Fiore M; Bylina E; Hoiczyk M; Cats A; Casali PG; Le Cesne A; Treckmann J; Stoeckle E; de Wilt JH; Sleijfer S; Tielen R; van der Graaf W; Verhoef C; van Coevorden F
    Ann Surg Oncol; 2013 Sep; 20(9):2937-43. PubMed ID: 23760587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver surgery in the multidisciplinary management of gastrointestinal stromal tumour.
    Cananzi FC; Belgaumkar A; Lorenzi B; Mudan S
    ANZ J Surg; 2014 Dec; 84(12):937-42. PubMed ID: 25444423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver surgery in the multidisciplinary management of gastrointestinal stromal tumour.
    Cananzi FC; Belgaumkar AP; Lorenzi B; Mudan S
    ANZ J Surg; 2014 Dec; 84(12):E1-8. PubMed ID: 23647808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [GIST: our experience].
    Rossi MT; Fasano G; Morlino A; Scutari F
    G Chir; 2009; 30(1-2):41-5. PubMed ID: 19272232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China.
    Du CY; Zhou Y; Song C; Wang YP; Jie ZG; He YL; Liang XB; Cao H; Yan ZS; Shi YQ
    Eur J Cancer; 2014 Jul; 50(10):1772-1778. PubMed ID: 24768330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of liver metastases of gastrointestinal stromal tumors (GIST).
    Vassos N; Agaimy A; Hohenberger W; Croner RS
    Ann Hepatol; 2015; 14(4):531-9. PubMed ID: 26019040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surgically managed gastrointestinal stromal tumors: a comparative and prognostic analysis.
    Hassan I; You YN; Shyyan R; Dozois EJ; Smyrk TC; Okuno SH; Schleck CD; Hodge DO; Donohue JH
    Ann Surg Oncol; 2008 Jan; 15(1):52-9. PubMed ID: 18000711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of surgical resection following imatinib treatment in patients with recurrent or metastatic gastrointestinal stromal tumors: results of propensity score analyses.
    Park SJ; Ryu MH; Ryoo BY; Park YS; Sohn BS; Kim HJ; Kim CW; Kim KH; Yu CS; Yook JH; Kim BS; Kang YK
    Ann Surg Oncol; 2014 Dec; 21(13):4211-7. PubMed ID: 24980089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic resection for metastatic gastrointestinal stromal tumors in the tyrosine kinase inhibitor era.
    Turley RS; Peng PD; Reddy SK; Barbas AS; Geller DA; Marsh JW; Tsung A; Pawlik TM; Clary BM
    Cancer; 2012 Jul; 118(14):3571-8. PubMed ID: 22086856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.